Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Facts Views Vis Obgyn ; 12(2): 111-118, 2020 Aug 05.
Article in English | MEDLINE | ID: mdl-32832925

ABSTRACT

As highlighted by European statistics, the employment of donor oocytes is a growing option for women who cannot make use of their own gametes. As the potential recipients are continuously increasing in number, a donor programme which satisfies this demand is mandatory. Improvements in cryopreservation techniques, like oocyte and embryo vitrification, have led to the overcoming of the sequence of stimulation-retrieval-transfer both from a spatial and a temporal point of view, with the development of cryobanks of oocytes permitting crossborder donation. However, while some studies report comparable success when using vitrified and fresh oocytes we still need to investigate whether the use of fresh oocytes give higher live birth rate than cryopreserved ones, when the same number of oocytes are given. The performance of embryo cryopreservation, conversely, seems to be more reliable. A novel approach based on the shipment of frozen sperm from the recipient's country to the oocyte donor's one, where fresh oocytes are inseminated and the resulting embryos frozen and transported back to the referring IVF centre to perform a frozen embryo transfer may be a good strategy. We believe that the use of frozen embryos from fresh oocytes could be associated with a higher cumulative live birth rate per cycle, while favouring personalised oocyte recipient care with a flexible number of oocytes assigned and limiting the burden of travelling abroad.

3.
Reprod Biomed Online ; 22(4): 389-98, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21353640

ABSTRACT

This study evaluated whether anti-Müllerian hormone (AMH) was differentially expressed in cumulus (CC) and granulosa (GC) cells from large antral and pre-ovulatory follicles collected from individual follicles in women undergoing in-vitro maturation (IVM) or IVF treatment. Expression studies of AMH, AMH receptor 2, FSH receptor, aromatase and androgen receptor were performed in CC in IVM patients where cumulus-oocyte-complex had expanded, CC in IVM patients where cumulus-oocyte-complex remained compacted, GC from immature follicles and CC and GC from IVF patients. Microarray data on corresponding GC and CC from follicles from IVF patients was included. AMH expression was significantly higher in CC than in GC from both mature and immature follicles and in CC from immature follicles than in CC from pre-ovulatory follicles from IVF patients (P < 0.05). AMH expression was significantly higher in CC that remained compacted compared with those that had expanded (P < 0.008). AMH was correlated to the expression of FSH receptor, androgen receptor and AMH receptor 2 but not to aromatase expression. The expression pattern of AMH receptor 2 reflected that of AMH. AMH may exert intrafollicular functions even in human large antral and pre-ovulatory follicles and may be related to follicular health.


Subject(s)
Anti-Mullerian Hormone/metabolism , Cumulus Cells/metabolism , Ovarian Follicle/growth & development , Reproductive Techniques, Assisted , Aromatase/metabolism , Blotting, Western , DNA, Complementary/genetics , Electrophoresis, Polyacrylamide Gel , Female , Humans , Linear Models , Microarray Analysis , Ovarian Follicle/metabolism , Polymerase Chain Reaction , Receptors, Androgen/metabolism , Receptors, FSH/metabolism , Receptors, Peptide/metabolism , Receptors, Transforming Growth Factor beta/metabolism
4.
Reprod Biomed Online ; 19(3): 343-51, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19778479

ABSTRACT

This study was designed to determine if the efficiency of in-vitro maturation (IVM) in women with normal ovaries can be improved by gonadotrophin administration. 400 women were randomly allocated in four groups: group A, non-primed cycles; group B, human chorionic gonadotrophin (HCG)-primed cycles; group C, FSH-primed cycles; and group D, FSH- plus HCG-primed cycles. There were significant differences in the IVM rate among the groups. In groups where HCG was used, the overall maturation rate was higher (57.9% in group B and 77.4% in group D; 48.4% in group A and 50.8% in group C) and the percentage of total available metaphase II-stage oocytes was higher (60.4% in group B and 82.1% in group D; 48.4% in group A and 50.8% in group C). The overall clinical pregnancy rate per transfer (CPR) was 18.3% and the implantation rate (IR) was 10.6%. There was a difference in CPR among the groups: group D (29.9%) versus group A (15.3%), P = 0.023; group D versus group B (7.6%), P < 0.0001; group D versus group C (17.3%), P = 0.046. The results of this study are clearly in favour of FSH plus HCG priming. FSH priming and HCG priming alone showed no significant effects on clinical outcome.


Subject(s)
Gonadotropins/administration & dosage , Oocytes/drug effects , Oogenesis/drug effects , Ovary/drug effects , Adult , Cells, Cultured , Chorionic Gonadotropin/administration & dosage , Drug Administration Schedule , Drug Combinations , Embryo Implantation/drug effects , Embryo Implantation/physiology , Embryo Transfer , Embryonic Development/drug effects , Female , Fertility Agents, Female/administration & dosage , Follicle Stimulating Hormone/administration & dosage , Health , Humans , Oocytes/cytology , Oocytes/physiology , Oogenesis/physiology , Ovary/physiology , Pregnancy , Pregnancy Rate
5.
Reprod Biomed Online ; 19(2): 171-80, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19712551

ABSTRACT

The success of reproductive technologies is facilitated by the cryopreservation of embryos and gametes. In Italy, where legislation prohibits zygote and embryo cryopreservation, clinics have extensively introduced oocyte cryopreservation. Two different strategies of oocyte cryopreservation are available: slow freezing or ultrarapid cooling (vitrification). Although the results are very encouraging with both methods, there is still controversy regarding both the procedure itself and the most suitable method to use. This study reports the routine application of the two different oocyte cryopreservation methods in programmes running in two consecutive periods. The study centre carried out 286 thawing cycles for a total of 1348 thawed oocytes cryopreserved by the slow-freezing method and 59 warming cycles for a total of 285 warmed oocytes cryopreserved by vitrification. Comparison of the outcomes obtained with the slow-freezing method versus vitrification in women who underwent IVF for infertility showed survival, fertilization, pregnancy and implantation rates of 57.9% versus 78.9% (P < 0.0001), 64.6% versus 72.8% (P = 0.027), 7.6% versus 18.2% (P = 0.021) and 4.3% versus 9.3% (P = 0.043) respectively. These results suggest that oocyte vitrification is associated with a better outcome than the slow-freezing method.


Subject(s)
Cryopreservation/methods , Oocytes , Female , Humans
6.
Reprod Biomed Online ; 18(2): 251-61, 2009 Feb.
Article in English | MEDLINE | ID: mdl-19192347

ABSTRACT

The in-vitro maturation protocol (IVM) is an intriguing tool in assisted reproduction since it omits the side-effects of drug stimulation and reduces the cost of the entire procedure, both in terms of time and patient/society costs. In the Biogenesi Reproductive Medicine Centre, the IVM technique has been applied for more than 3 years, obtaining successful results in terms of maturation and fertilization rates, number of pregnancies and healthy babies born. At present, IVM is widely accepted in polycystic ovary and polycystic ovarian syndrome patients but its application in other women is still controversial. This study has been carried out in order to determine the efficiency of unstimulated IVM in women with morphologically and endocrinologically normal ovaries. Body mass index, basal FSH and oestradiol concentrations, antral follicle count, endometrial thickness and lead follicle size were correlated with the outcome of the procedure so as to obtain useful criteria to select women with regular cycles for an IVM technique. It was found that basal oestradiol concentration, FSH concentration and antral follicle count are useful criteria in deciding whether to start and continue the procedure, while lead follicle size and endometrial thickness are important criteria in deciding the timing of oocyte retrieval.


Subject(s)
Infertility/diagnosis , Oocytes/cytology , Oogenesis/physiology , Ovary/physiology , Adult , Cells, Cultured , Cytological Techniques , Female , Humans , Male , Ovulation Induction/adverse effects , Pregnancy , Prognosis , Retrospective Studies , Sperm Injections, Intracytoplasmic , Treatment Outcome , Young Adult
7.
Reprod Biomed Online ; 13(2): 159-65, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16895627

ABSTRACT

In March 2004, a new law was introduced in Italy to regulate assisted reproduction; at present it is impossible to use more than a maximum of three oocytes per IVF cycle, nor can embryos or prezygotes (2PN cells) be selected or cryopreserved. The prohibitions introduced by the new law have, on the one hand, reduced the expectations of success of current techniques and, on the other hand, stimulated clinicians and embryologists to work on new therapeutic strategies so as to offer the highest chances of success with the lowest risks. In-vitro maturation (IVM) of oocytes fits very well with these new requirements: ovarian stimulation is avoided and the handling of spare oocytes is facilitated. The IVM protocol is an intriguing alternative to conventional IVF techniques, since it removes the side-effects of drug stimulation, especially ovarian hyperstimulation syndrome, and it also reduces the costs of the entire procedure, both in terms of 'time consumption' and 'patient/society costs for drugs'. In the authors' IVF centre the IVM technique has been used for more than a year, with significant success in terms of maturation and fertilization rates, percentage of embryo transfers, number of pregnancies and, finally, healthy babies born.


Subject(s)
Fertilization in Vitro/methods , Infertility, Female/therapy , Adult , Embryo Transfer , Female , Fertilization in Vitro/economics , Fertilization in Vitro/legislation & jurisprudence , Humans , Italy , Oocytes/growth & development , Ovulation Induction/adverse effects , Ovulation Induction/economics , Pregnancy , Pregnancy Rate , Pregnancy, Multiple/statistics & numerical data
SELECTION OF CITATIONS
SEARCH DETAIL
...